Hemab Therapeutics Holdings Inc (COAG) Stock AnalysisCOAGHemab Therapeutics Holdings Inc

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets. It operates in the Healthcare sector.

Hemab Therapeutics appears to be a good buy right now due to its recent price of $31.62, which is significantly below the analyst price targets of $64 and $60. Additionally, the company has a strong cash position of $457.5 million, which is expected to fund operations into 2029, providing a safety net for ongoing development costs. However, the main risk is its negative earnings, with a reported loss of $0.80 per share in Q2 2026, which reflects ongoing financial pressure.